CClinicalTrials.gg
RecruitingNCT05655325EXECUpdated Sep 8, 2026

Accelerated Age-related Cognitive Decline: Impact of Exercise on Executive Function and Neuroplasticity

An interventional study of Home-based walking exercise and Attention control in Mild Cognitive Impairment and Chronic Kidney Diseases, sponsored by Columbia University. Recruiting at 2 sites in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Columbia University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Study summary

The purpose of this study is to see if 6 months of home-based walking will improve memory, and brain structure and function, compared to health education in older adults that have chronic kidney disease and mild cognitive impairment.

Read the detailed description

Following informed consent, participants will undergo tests for heart health, physical function, memory testing, and brain structure and function using imaging (taking pictures of the brain with an MRI). Following these tests participants are randomized to a home-based walking program or health education for 6 months. Participants are given a fitness tracker and gets ongoing telephone coaching during the 6 months. After 6 months the tests are repeated.

02

Conditions studied

  • Mild Cognitive Impairment
  • Chronic Kidney Diseases

Keywords

  • mild cognitive impairment
  • chronic kidney disease
  • exercise
  • Lifestyle behavior
  • home-based exercise
03

In context

Cognitive Dysfunction

3,845 studies on the registry are indexed under Cognitive Dysfunction; 1,100 are open to participants now.

This study's planned enrollment of 144 is above the median of 64 across 2,810 interventional studies indexed under Cognitive Dysfunction.

Browse Cognitive Dysfunction studies →

Lead sponsor

Columbia University is the lead sponsor of 1,103 studies on the registry; 193 are open to participants now.

Of its 172 completed or terminated interventional studies of FDA-regulated products, 142 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

    • Diagnosed stage 3-4 chronic kidney disease (CKD, estimated glomerular filtration rate (eGFR) \<60 to 20 ml/min);

      • >55 yrs of age
      • Mild cognitive impairment (18-26 on the MOCA)
      • ability to undergo an MR
      • no history of major head trauma (No head trauma/concussion with loss of consciousness)
      • Speaks, reads, writes English

Exclusion criteria

Exclusion Criteria:

    • Diagnosed Dementia or a Clinical Dementia Rating Scale score of \<2, or a MOCA of \<18

      • Participating in a supervised exercise program with intent to increase fitness levels 3 days/week,
      • Requires assistive ambulation
      • Limited exercise capacity due to claudication; unstable angina, severe arthritis, extreme dyspnea on exertion, unstable coronary artery disease
      • Class III-IV heart failure
      • History of uncontrolled sustained arrhythmias, severe/symptomatic aortic or mitral stenosis, hypertrophic obstructive cardiomyopathy, severe pulmonary hypertension, active myocarditis/pericarditis, thrombophlebitis, and recent systemic/pulmonary embolus
      • Resting systolic BP >200 mmHg or resting diastolic BP >110 mmHg
      • Any unforeseen illness or disability that would preclude cognitive testing or exercise training
      • One or more contraindication for MRI; cardiac pacemaker, aneurysm clip, cochlear implants, shrapnel, history of metal fragments in eyes, neurostimulators, diagnosed claustrophobia (MRI only)
      • Any self-reported major psychiatric disorders requiring medical therapy (e.g. schizophrenia, bipolar disorder).
      • Self-reported new diagnosis of clinical depression within 3 months of enrollment or unstable clinical depression requiring medication adjustment within 3 months of enrollment
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    Home-based walking exercise

    A 6-month partially supervised walking exercise training using a tapered approach. Participants begin with exercising (walking) in person, on-site one time per week and 3 times per week at home for a minimum exercise dosage of 30 minutes of accumulated exercise per session during month 1. During month 2, participants will exercise on-site once every other week and 3-4 times per week at home a minimum exercise dosage of 30 minutes of accumulated exercise per session. During months 2-6, participants will exercise at home 4 times per week for a minimum exercise dosage of 30 minutes of accumulated exercise per session and they will receive a phone call every two weeks to help coach and address any problems. Participants will receive a Fitbit fitness tracker that will be used to deliver their personalized exercise program, exercise monitoring, feedback, and motivational messages.

    Behavioral: Home-based walking exercise

  • Placebo comparator
    Health education

    The health education group will receive the same amount of contact hours as the intervention group. The attention control group will receive health education and stretching exercises. Participants will be in person, on-site one time per week during month 1 for about 30 minutes. During month 2, participants will attend the health education on-site once every other week for about 30 minutes. During months 2-6 participants will receive a phone call every two weeks to help remind about the health education. Participants will receive a Fitbit fitness tracker that will be used for exercise monitoring.

    Other: Attention control

Interventions

  • BehavioralHome-based walking exercise

    A 6-month partially supervised walking exercise program using a tapered approach.Participants will begin exercise (walking) at a relatively low intensity and progress to moderate intensity. Intensity will start at 40% and progress as tolerated up to 60-70%. Rating of perceived exertion of 12-14 (fairly light to moderate) will be used to aid intensity (Rating of perceived exertion 6-20 scale). This is an accepted method for achieving desired exercise intensity. Participants will progress over time to exercise 3-4/week for 30-45 minutes. The exercise program may need to be adjusted for (e.g. 10 minutes of exercise 3 times), to achieve the minimum exercise dose of 30 minutes. This will be determined for each individual participants as needed.

  • OtherAttention control

    Health education and stretching

06

What researchers measure

Primary outcomes

  1. Change in Executive Function from baseline

    Composite score from Phonemic and Semantic Fluency total correct words; Trail Making Test Part B (TMT-B) time to completion; Digit Span subtest backwards total score. The composite executive functioning score will be created by converting these four individual executive cognitive scores (phonemic and Semantic fluency score), digit span backward subtest, and trail making test part B (following directionality conversion)) to standardized z scores and then averaging the standardized z scores. Z-score range from -3 to +3. Higher score is better.

    Time frame: Change from baseline at 6 months

  2. Change in processing speed from baseline

    Trail making test part A (TMT-A) time to completion in seconds. Faster completion is better.

    Time frame: Change from baseline at 6 months

  3. Change in attention/information processing from baseline

    Digit symbol substitution test total number correct. Higher number is better.

    Time frame: Change from baseline at 6 months

  4. Change in Learning and Memory short recall

    California verbal learning test-II, short recall total number of words correct. Higher number is better.

    Time frame: Change from baseline at 6 months

  5. Change in Learning and Memory long recall

    California verbal learning test-II long recall total number of words correct. Higher number is better.

    Time frame: Change from baseline at 6 months

  6. Change in Learning and Memory learning slope

    California verbal learning test-II leaning slope (average number of new words recalled during five consecutive learning trials). Higher number is better.

    Time frame: Change from baseline at 6 months

  7. Change in Learning and Memory recognition memory discrimination

    California verbal learning test-II recognition memory discrimination total number of words correct. Higher number is better.

    Time frame: Change from baseline at 6 months

  8. Change in global cognitive function

    Composite score from Phonemic and Semantic Fluency total correct words; Trail Making Test Part B time to completion; Digit Span subtest backwards total score; Digit symbol substitution test total correct and trail making test part A time to completion; California verbal learning test-II, short and long recall, leaning slope, recognition memory discrimination total correct. The composite global cognitive score will be created by converting these 10 individual cognitive scores (following directionality change of TMT-A and TMT-B) to standardized z scores and then averaging the standardized z scores. Z score range from -3 to +3. Higher score is better.

    Time frame: Change from Baseline to 6 months

Secondary outcomes

  1. Change from baseline to 6-months in white matter fractional anisotropy.

    Quantify change from baseline to 6-months in white matter integrity fractional anisotropy using diffusion tensor MRI imaging. Range 0-1. Higher number is better.

    Time frame: Change from baseline to 6 months

  2. Change from baseline to 6-months in white matter mean diffusivity.

    Quantify change from baseline to 6-months in white matter integrity mean diffusivity using diffusion tensor MRI imaging. Range 0-1. Lower number is better.

    Time frame: Change from baseline to 6 months

  3. Changes from baseline to 6-months in functional connectivity

    Quantify change from baseline to 6-months in functional connectivity using functional MRI (fMRI). Range 0-1. Higher score is better.

    Time frame: Change from Baseline to 6 months

  4. Change from baseline to 6-months in cerebral blood flow.

    Quantify changes from baseline to 6-months in cerebral blood flow using perfusion MRI arterial spin labeling in mL/100g/min. Higher is better.

    Time frame: Change from baseline to 6 months

  5. Change from baseline to 6-months in hippocampal volume

    Quantify change from baseline to 6-months in hippocampal volume using morphometry using 3D T1-weighted MRI in milliliters cubed. Higher number is better.

    Time frame: Change from baseline to 6 months

07

Study locations

2 of 2 sites recruiting
  • Georgetown University
    Washington D.C., District of Columbia 20057, United States
    Recruiting
  • Columbia University
    New York, New York 10023, United States
    • Ulf G Bronas, PhD · Contact · ub2154@cumc.columbia.edu
    • Ulf G Bronas, PhD · Principal investigator
    • Shayan Shirazian, MD · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data (IPD) will be made available based on each publication. The PI will share data through sharing requests. All data will be properly de-identified before sharing. Data sharing requests may be granted to those that 1) have a detailed research plan for the requested data, 2) have human subjects training, and 3) have institutional review board (IRB) approval from their home institution. Data sharing requests will be furnished with a data-sharing agreement approved by the University of Illinois Chicago IRB that contains commitments to: 1) Using the data for research purposes only (no commercial use of the data), 2) not attempting to re-identify any participant, 3) securing the data using appropriate technology, and 4) destroying or returning the data after analyses. Other stipulations may be added to the data-sharing agreement if deemed necessary. Data may be shared as a complete or partial dataset depending on the request.

Supporting information: Study protocol, Sap

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05655325
Lead sponsor
Columbia University
Collaborators
National Institute on Aging (NIA), Georgetown University
Responsible party
Shayan Shirazian (Associate Professor of Medicine, Columbia University) — Principal investigator
First posted
Dec 19, 2022
Start date
Jun 18, 2024
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Sep 8, 2026

Study contacts

Ulf G Bronas, PhD
Contact
ub2154@cumc.columbia.edu
212-305-0750
Ulf G Bronas, PhD
study chair · Columbia University
Shayan Shirazian, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion